The VOICE study ("Vaginal and Oral Interventions to Control the Epidemic") study was a phase II clinical trial that examined the use of tenofovir vaginal gel. It began in 2009 and was stopped in 2011 because of low adherence. See Jeanne M. Marrazzo, Gita Ramjee, Barbra A. Richardson, Kailazarid Gomez, Nyaradzo Mgodi, Gonasagrie Nair, Thesla Palanee, et al. “Tenofovir-Based Preexposure Prophylaxis for HIV Infection among African Women.” New England Journal of Medicine 372, no. 6 (February 5, 2015): 509–18. doi:10.1056/NEJMoa1402269.
Found 1 search result(s) for "VOICE study".
6.1 Sharon Hillier — Development and Application of Pre-exposure Prophylaxis (PrEP)
(HIV/AIDS Research: Its History & Future Meeting)
... effective by 00:09:00 Salim Karim and his team in the CAPRISA 004 study (2007–2010) with a 39% efficacy with broad confidence intervals. (14) In the VOICE trial, we saw a 15% efficacy. Like in Salim's study, we saw about ...
Apr 27, 2021
... effective by 00:09:00 Salim Karim and his team in the CAPRISA 004 study (2007–2010) with a 39% efficacy with broad confidence intervals. (14) In the VOICE trial, we saw a 15% efficacy. Like in Salim's study, we saw about ...
Apr 27, 2021